Low dose IL-2 therapy restores regulatory T cells in patients with systemic lupus erythematosus in a dose-dependent manner: a phase IIb trial

Xia Zhang(Peking University), Jing He(Peking University), Yan Ding(Hubei University of Medicine), T H Li(First Affiliated Hospital of Zhengzhou University), Guanmin Gao(First Affiliated Hospital of Zhengzhou University), Tongjun Mao(First Affiliated Hospital of Wannan Medical College), Z A Li(China Pharmaceutical University), Ke Xu(Shanxi Academy of Medical Sciences), Yucui Li(Shanxi Academy of Medical Sciences), Wenping Pan(Shandong Mental Health Center), Q Wang(Peking University Shenzhen Hospital), Dongbin Jiang(First Affiliated Hospital of Zhengzhou University), Yueming Cai(Peking University Shenzhen Hospital), Lingyan Lei(Hebei Medical University), Yifan Wang(Peking University), Wenqiang Fan(Xinxiang Central Hospital), Yongfu Wang(Peking University), Yuan Jia(Peking University), Xiao Gao(Xinxiang Central Hospital), Xiaolin Sun(Peking University), Rong Mu(Peking University), Huifang Guo(Hebei Medical University), Na Zhang(Tianjin Medical University General Hospital), Wei Wei(Tianjin Medical University General Hospital), Ruijun Zhang(First Affiliated Hospital of Wannan Medical College), Juan He(Peking University), Miaomiao Ma(Xinxiang Central Hospital), Kuanting Wang(Peking University Shougang Hospital), Hui Wang(Baotou Medical College), Ruiling Feng(Peking University)
Nature Communications
April 21, 2026
Cited by 0


Related Papers